News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Helix Biopharma Signs L-DOS47 Manufacturing Agreement With QSV Biologics, Ltd.
December 20, 2005
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Helix BioPharma Corp. (Helix; TSX, FSE: "HBP") today announced that it has signed an agreement with Edmonton, Alberta-based QSV Biologics (QSV) to develop the cGMP manufacturing process for L-DOS47.
Twitter
LinkedIn
Facebook
Email
Print
Alliances
MORE ON THIS TOPIC
M&A
Novartis To ‘Bolster’ Neuromuscular Pipeline With $12B Avidity Acquisition
October 26, 2025
·
2 min read
·
Heather McKenzie
Deals
Lilly Dives Deeper Into Gene Therapy With up to $262M Adverum Buy
October 24, 2025
·
2 min read
·
Heather McKenzie
CAR-T
Regeneron Cans 2seventy-Acquired CAR T Candidate for Lymphoma in ‘Strategic’ Move
October 24, 2025
·
2 min read
·
Tristan Manalac
Earnings
Sanofi’s Legacy Vaccine Sales Decline As Americans Skip Flu Shots
October 24, 2025
·
2 min read
·
Annalee Armstrong
